https://www.selleckchem.com/
Based on the above analyses, a m6A-based signature to predict the overall survival (OS) in LUAD was successfully established. Among the 479 cases, we found that most of the m6A-related genes were differentially expressed between tumor and non-tumor tissues. Six genes, HNRNPC, METTL3, YTHDC2, KIAA1429, ALKBH5, and YTHDF1 were screened to build a risk scoring signature, which is strongly related to the clinical features pathological stages (p less then 0.05), M stages (p less then 0.05), T stages (p less then 0.05), gender (p = 0.04), and survival outcome (
Like
Comment
Share
